No Record Found
CALLS | PUTS | |||||||||
Total OI | Chg in Ol | Chg % Ol | LTP | Chg % | Strike Price | Chg % | LTP | Chg % OI | Chg in Ol | Total OI |
No Record Found
sector: Pharmaceuticals
as on 12/10/2019 3:29:51 PM
₹ 22.6 -0.55 -2.38No Record Found
No Record Found
Resolution Type | Desc. of Resolution | Lias Recommendation |
---|
Invest wise with Expert advice
Get better recommendations Make better investments.
Get better recommendations Make better investments.
By continuing, I accept the Terms & Conditions and agree to receive communication on Whatsapp
Demat Account
Trading Account
PROMOTER - TOTAL56.08%
Indian: 56.08%
Foreign: 0%
NON-PROMOTER - TOTAL 42.46%
Institutions: 4.01%
Non-Institutions: 38.45%
CUSTODIES - 1.46%
Custodies: 1.46%
Y/e 31 Mar ( In .Cr) | -- | -- | -- | -- |
---|---|---|---|---|
Revenue | -- | -- | -- | -- |
yoy growth (%) | -- | -- | -- | -- |
Raw materials | -- | -- | -- | -- |
As % of sales | -- | -- | -- | -- |
Employee costs | -- | -- | -- | -- |
As % of sales | -- | -- | -- | -- |
Other costs | -- | -- | -- | -- |
As % of sales | -- | -- | -- | -- |
Operating profit | -- | -- | -- | -- |
OPM | -- | -- | -- | -- |
Depreciation | -- | -- | -- | -- |
Interest expense | -- | -- | -- | -- |
Other income | -- | -- | -- | -- |
Profit before tax | -- | -- | -- | -- |
Taxes | -- | -- | -- | -- |
Tax rate | -- | -- | -- | -- |
Minorities and other | -- | -- | -- | -- |
Adj. profit | -- | -- | -- | -- |
Exceptional items | -- | -- | -- | -- |
Net profit | -- | -- | -- | -- |
yoy growth (%) | -- | -- | -- | -- |
NPM | -- | -- | -- | -- |
Y/e 31 Mar ( In .Cr) | -- | -- | -- | -- |
---|---|---|---|---|
Equity capital | -- | -- | -- | -- |
Preference capital | -- | -- | -- | -- |
Reserves | -- | -- | -- | -- |
Net worth | -- | -- | -- | -- |
Minority interest | -- | -- | -- | -- |
Debt | -- | -- | -- | -- |
Deferred tax liabilities (net) | -- | -- | -- | -- |
Total liabilities | -- | -- | -- | -- |
Fixed assets | -- | -- | -- | -- |
Intangible assets | -- | -- | -- | -- |
Investments | -- | -- | -- | -- |
Deferred tax asset (net) | -- | -- | -- | -- |
Net working capital | -- | -- | -- | -- |
Inventories | -- | -- | -- | -- |
Inventory Days | -- | -- | -- | -- |
Sundry debtors | -- | -- | -- | -- |
Debtor days | -- | -- | -- | -- |
Other current assets | -- | -- | -- | -- |
Sundry creditors | -- | -- | -- | -- |
Creditor days | -- | -- | -- | -- |
Other current liabilities | -- | -- | -- | -- |
Cash | -- | -- | -- | -- |
Total assets | -- | -- | -- | -- |
Y/e 31 Mar ( In .Cr) | -- | -- | -- | -- |
---|---|---|---|---|
Profit before tax | -- | -- | -- | -- |
Depreciation | -- | -- | -- | -- |
Tax paid | -- | -- | -- | -- |
Working capital | -- | -- | -- | -- |
Other operating items | -- | -- | -- | -- |
Operating cashflow | -- | -- | -- | -- |
Capital expenditure | -- | -- | -- | -- |
Free cash flow | -- | -- | -- | -- |
Equity raised | -- | -- | -- | -- |
Investments | -- | -- | -- | -- |
Debt financing/disposal | -- | -- | -- | -- |
Dividends paid | -- | -- | -- | -- |
Other items | -- | -- | -- | -- |
Net in cash | -- | -- | -- | -- |
Y/e 31 Mar ( In .Cr) | -- | -- | -- | -- |
---|---|---|---|---|
Growth matrix (%) | -- | -- | -- | -- |
Revenue growth | -- | -- | -- | -- |
Op profit growth | -- | -- | -- | -- |
EBIT growth | -- | -- | -- | -- |
Net profit growth | -- | -- | -- | -- |
Profitability ratios (%) | -- | -- | -- | -- |
OPM | -- | -- | -- | -- |
EBIT margin | -- | -- | -- | -- |
Net profit margin | -- | -- | -- | -- |
RoCE | -- | -- | -- | -- |
RoNW | -- | -- | -- | -- |
RoA | -- | -- | -- | -- |
Per share ratios (₹) | -- | -- | -- | -- |
EPS | -- | -- | -- | -- |
Dividend per share | -- | -- | -- | -- |
Cash EPS | -- | -- | -- | -- |
Book value per share | -- | -- | -- | -- |
Valuation ratios | -- | -- | -- | -- |
P/E | -- | -- | -- | -- |
P/CEPS | -- | -- | -- | -- |
P/B | -- | -- | -- | -- |
EV/EBIDTA | -- | -- | -- | -- |
Payout (%) | -- | -- | -- | -- |
Dividend payout | -- | -- | -- | -- |
Tax payout | -- | -- | -- | -- |
Liquidity ratios | -- | -- | -- | -- |
Debtor days | -- | -- | -- | -- |
Inventory days | -- | -- | -- | -- |
Creditor days | -- | -- | -- | -- |
Leverage ratios | -- | -- | -- | -- |
Interest coverage | -- | -- | -- | -- |
Net debt / equity | -- | -- | -- | -- |
Net debt / op. profit | -- | -- | -- | -- |
Cost breakup (₹) | -- | -- | -- | -- |
Material costs | -- | -- | -- | -- |
Employee costs | -- | -- | -- | -- |
Other costs | -- | -- | -- | -- |
Particulars ( Rupees In Crores.) | -- | -- | -- | -- | -- |
---|---|---|---|---|---|
Gross Sales | -- | -- | -- | -- | |
Excise Duty | -- | -- | -- | -- | |
Net Sales | -- | -- | -- | -- | |
Other Operating Income | -- | -- | -- | -- | |
Other Income | -- | -- | -- | -- | |
Total Income | -- | -- | -- | -- | |
Total Expenditure ** | -- | -- | -- | -- | |
PBIDT | -- | -- | -- | -- | |
Interest | -- | -- | -- | -- | |
PBDT | -- | -- | -- | -- | |
Depreciation | -- | -- | -- | -- | |
Minority Interest Before NP | -- | -- | -- | -- | |
Tax | -- | -- | -- | -- | |
Deferred Tax | -- | -- | -- | -- | |
Reported Profit After Tax | -- | -- | -- | -- | |
Minority Interest After NP | -- | -- | -- | -- | |
Net Profit after Minority Interest | -- | -- | -- | -- | |
Extra-ordinary Items | -- | -- | -- | -- | |
Adjusted Profit After Extra-ordinary item | -- | -- | -- | -- | |
EPS (Unit Curr.) | -- | -- | -- | -- | |
Book Value (Unit Curr.) | -- | -- | -- | -- | |
Dividend (%) | -- | -- | -- | -- | |
Equity | -- | -- | -- | -- | |
Public Shareholding (Number) | -- | -- | -- | -- | |
Public Shareholding (%) | -- | -- | -- | -- | |
Pledged/Encumbered - No. of Shares | -- | -- | -- | -- | |
Pledged/Encumbered - % in Total Promoters Holding | -- | -- | -- | -- | |
Pledged/Encumbered - % in Total Equity | -- | -- | -- | -- | |
Non Encumbered - No. of Shares | -- | -- | -- | -- | |
Non Encumbered - % in Total Promoters Holding | -- | -- | -- | -- | |
Non Encumbered - % in Total Equity | -- | -- | -- | -- | |
PBIDTM(%) | -- | -- | -- | -- | |
PBDTM(%) | -- | -- | -- | -- | |
PATM(%) | -- | -- | -- | -- |
No Record Found
Particulars ( Rupees In Crores.) | -- | -- | -- | -- | -- |
---|---|---|---|---|---|
Gross Sales | -- | -- | -- | -- | |
Excise Duty | -- | -- | -- | -- | |
Net Sales | -- | -- | -- | -- | |
Other Operating Income | -- | -- | -- | -- | |
Other Income | -- | -- | -- | -- | |
Total Income | -- | -- | -- | -- | |
Total Expenditure ** | -- | -- | -- | -- | |
PBIDT | -- | -- | -- | -- | |
Interest | -- | -- | -- | -- | |
PBDT | -- | -- | -- | -- | |
Depreciation | -- | -- | -- | -- | |
Minority Interest Before NP | -- | -- | -- | -- | |
Tax | -- | -- | -- | -- | |
Deferred Tax | -- | -- | -- | -- | |
Reported Profit After Tax | -- | -- | -- | -- | |
Minority Interest After NP | -- | -- | -- | -- | |
Net Profit after Minority Interest | -- | -- | -- | -- | |
Extra-ordinary Items | -- | -- | -- | -- | |
Adjusted Profit After Extra-ordinary item | -- | -- | -- | -- | |
EPS (Unit Curr.) | -- | -- | -- | -- | |
Book Value (Unit Curr.) | -- | -- | -- | -- | |
Dividend (%) | -- | -- | -- | -- | |
Equity | -- | -- | -- | -- | |
Public Shareholding (Number) | -- | -- | -- | -- | |
Public Shareholding (%) | -- | -- | -- | -- | |
Pledged/Encumbered - No. of Shares | -- | -- | -- | -- | |
Pledged/Encumbered - % in Total Promoters Holding | -- | -- | -- | -- | |
Pledged/Encumbered - % in Total Equity | -- | -- | -- | -- | |
Non Encumbered - No. of Shares | -- | -- | -- | -- | |
Non Encumbered - % in Total Promoters Holding | -- | -- | -- | -- | |
Non Encumbered - % in Total Equity | -- | -- | -- | -- | |
PBIDTM(%) | -- | -- | -- | -- | |
PBDTM(%) | -- | -- | -- | -- | |
PATM(%) | -- | -- | -- | -- |
No Record Found
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd | 1,529.55 | 87.85 | 3,61,915.69 | 721.31 | 0.76 | 4,903.66 | 100.23 |
Cipla Ltd | 1,425.00 | 34.98 | 1,15,033.60 | 1,114.14 | 0.60 | 3,798.31 | 320.56 |
Dr Reddys Laboratories Ltd | 6,315.00 | 26.62 | 1,05,928.76 | 475.20 | 0.63 | 4,083.10 | 1,361.85 |
Divis Laboratories Ltd | 3,958.15 | 76.89 | 1,04,873.36 | 358.00 | 0.76 | 1,808.00 | 474.52 |
Zydus Lifesciences Ltd | 1,026.60 | 37.33 | 1,00,321.53 | 450.40 | 0.61 | 2,225.10 | 145.11 |
A demerged entity from Piramal Healthcare Limited (Formerly known as Nicholas Piramal India Limited) is now known as Piramal Life Sciences Limited (PLSL). Incorporated on 27th June 2001 under the name and style of NPIL Research and Development Private Limited as an independent research-driven drug company, it has state-of-the-art high-performance instruments and equipment R&D laboratories built over 2,00,000 square-feet of space in Mumbai, India engaged in drug discovery and development. PLSL is focused on four therapeutic areas namely Cancer, Diabetes, Inflammation and Infectious Diseases. The Company has a pipeline of fourteen compounds, including four in clinical trials. The Goregaon facility was built at a cost of nearly Rs. 1 billion and opened its doors at the end of 2004. In January 2007, PHL signed a drug development agreement with Eli Lilly & Co. to develop and commercialize a select group of Lillys pre-clinical drug candidates spanning multiple therapeutic areas; the same was transferred to and vested in PLSL. The New Chemical Entity (NCE) Research unit of Piramal Healthcare Limited was demerged to the company with effect from 1st April of the year 2007. The Companys status was converted from private limited to a public limited on 20th October 2007 and consequent deletion of the word private from the name. Merck & PLSL had entered into a research and development collaboration agreement in November 2007 to discover and develop new drugs for two new oncology targets... Read More
Reports by Piramal Phytocare Ltd(Merged)
Reports by Piramal Phytocare Ltd(Merged)
No Record Found
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Copyright © IIFL Securities Ltd. All rights Reserved.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This certificate demonstrates that IIFL as an organization has defined and put in place best-practice information security processes.
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Copyright © IIFL Securities Ltd. All rights Reserved.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This certificate demonstrates that IIFL as an organization has defined and put in place best-practice information security processes.